Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $682.28M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.16M
Average 0.08M
Returns on capital
Nuvectis Pharma, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-143.6%
avg -73.1%
ROIC
-149.8%
avg -146.9%
ROA
-83.4%
avg -98.1%
Analysis
ROA is currently the strongest return metric at -83.4% versus its period average of -98.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Ron Bentsur | Co-Founder, Chairman, Chief Executive Officer & President | USD 1.19M | 60 | 3.69M | 13.91% |
Shay Shemesh | Co-Founder, Executive Vice President, Chief Development & Operations Officer | USD 749.24K | 42 | 1.79M | 6.76% |
Enrique Poradosu | Co-Founder, Executive Vice President, Chief Scientific & Business Officer | USD 749.24K | 59 | 1.81M | 6.81% |
Michael Carson | Vice President of Finance | — | 50 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 30, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$1.17M
Sells
0
$0.00
Net Transaction Value
+$1.17M
Net buying
Most Active
Mosseri Marlio Charles
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jun 30, 26Jun 30, 2026 | Mosseri Marlio Charles Indirect | Buy | $916K$916,000.00 |
| Jun 30, 26Jun 30, 2026 | BENTSUR RON Direct | Buy | $250K$250,000.00 |
Summary
Insiders reported 2 buys worth $1.17M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $1.17M. Mosseri Marlio Charles was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Nuvectis Pharma, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about NVCT's management, answered from reported figures.
Who manages NVCT?
Nuvectis Pharma, Inc. (NVCT) lists 4 active executives. The top listed executive is Ron Bentsur, Co-Founder, Chairman, Chief Executive Officer & President.
Are NVCT insiders buying or selling?
Recent insider activity shows net buying of $11.21M.
Continue the stock analysis
Jump to another research area for this company.